BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27119128)

  • 1. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Preface.
    Ahmad A; Gadgeel SM
    Adv Exp Med Biol; 2016; 890():v-vi. PubMed ID: 27119128
    [No Abstract]   [Full Text] [Related]  

  • 2. How Targeted Therapies Are Changing Treatment for Non-Small Cell Lung Cancer.
    Becze E
    ONS Connect; 2016 Feb; 31(2):24-5. PubMed ID: 26930998
    [No Abstract]   [Full Text] [Related]  

  • 3. Epigenetics in Personalized Management of Lung Cancer.
    Ahmad A
    Adv Exp Med Biol; 2016; 890():111-22. PubMed ID: 26703801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized therapy.
    Ujhazy P; Herbst R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S401-3. PubMed ID: 23160334
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalized medicine: Special treatment.
    Eisenstein M
    Nature; 2014 Sep; 513(7517):S8-9. PubMed ID: 25208073
    [No Abstract]   [Full Text] [Related]  

  • 6. Current practice in and considerations for personalized medicine in lung cancer: From the patient's molecular biology to patient values and preferences.
    Carrera PM; Ormond M
    Maturitas; 2015 Sep; 82(1):94-9. PubMed ID: 25981825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abstracts of the AACR (American Association for Cancer Research)-IASLC (International Association for the Study of Lung Cancer) Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine. January 8-11, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 Feb; 18(3 Suppl):IA1-23, PR1-6, A1-46, B1-46. PubMed ID: 23534066
    [No Abstract]   [Full Text] [Related]  

  • 8. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
    Santarpia M; Altavilla G; Pitini V; Rosell R
    Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
    Wakelee H; Loo BW; Kernstine KH; Putnam JB; Edelman MJ; Vokes EE; Schiller JH; Baas P; Saijo N; Adjei A; Goss G; Choy H; Gandara DR
    Clin Lung Cancer; 2009 Nov; 10(6):395-404. PubMed ID: 19900856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics in the treatment of lung cancer: an update.
    Morales-Espinosa D; García-Román S; Karachaliou N; Rosell R
    Pharmacogenomics; 2015; 16(15):1751-60. PubMed ID: 26427522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current readings: Window-of-opportunity trials for thoracic malignancies.
    Tsao AS
    Semin Thorac Cardiovasc Surg; 2014; 26(4):323-30. PubMed ID: 25837547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successes and limitations of targeted cancer therapy in lung cancer.
    Suda K; Mitsudomi T
    Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro A
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is precision medicine ready for use in breast cancer?
    Pusztai L
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):964-966. PubMed ID: 28212357
    [No Abstract]   [Full Text] [Related]  

  • 15. Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.
    Bernicker E
    Arch Pathol Lab Med; 2016 Mar; 140(3):245-8. PubMed ID: 26927719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Substantiation of Expressive Markers Use to Personalize Lung Cancer Chemotherapy].
    Tsyganov MM; Rodionov EO; Miller SV; Litvyakov NV
    Antibiot Khimioter; 2015; 60(9-10):38-45. PubMed ID: 27141638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Diagnosis and Management of Breast Cancer.
    McDonald ES; Clark AS; Tchou J; Zhang P; Freedman GM
    J Nucl Med; 2016 Feb; 57 Suppl 1():9S-16S. PubMed ID: 26834110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
    Gadgeel SM
    Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM; Lin E; Ong FS
    Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targeted agents and biologic therapies for lung cancer.
    Somaiah N; Simon GR
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1758-85. PubMed ID: 22005529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.